文献速递神经肿瘤

TRAF3IP3 高表达预测胶质瘤患者不良预后

High TRAF3IP3 Level Predicts Poor Prognosis of Patients with Gliomas.
PubMed 文献 · World Neurosurg · 2021-01-12

基于 TCGA 和 GTEx 的 RNA-seq 数据,比较 670 例胶质瘤与 1157 例正常组织中 TRAF3IP3 表达,发现其在胶质瘤中高表达(P < 0.001),且与更高 WHO 级别、IDH 野生型、1p/19q 非共缺失等不良临床病理特征相关,高表达者无进展生存、无病生存和总生存均更差。

要点

  • TRAF3IP3 在胶质瘤中高表达,与不良临床病理特征显著相关。
  • 高表达 TRAF3IP3 提示无进展生存、无病生存和总生存更差。
  • TRAF3IP3 可能是胶质瘤预后潜在生物标志物。

核心结论

  • TRAF3IP3 在胶质瘤发生发展中起重要作用,可能是胶质瘤预后的潜在生物标志物。

研究设计与样本

  • 基于 TCGA 和 GTEx 的 RNA-seq 数据,纳入 670 例胶质瘤和 1157 例正常组织进行表达比较与预后分析。

主要发现

  • TRAF3IP3 在胶质瘤中高表达(P < 0.001)。
  • TRAF3IP3 高表达表型组显著富集 JAK-STAT、干扰素-γ、凋亡、P53、PD-1 和 CTLA-4 六条信号通路。

临床怎么用

  • TRAF3IP3 高表达或可作为胶质瘤预后风险评估的分子标志物,辅助识别高危患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tumor necrosis factor receptor-related factor 3 (TRAF3) interacting protein 3 (TRAF3IP3) is involved in the development of immune tissues and the immune response of the body. Downregulated expression of TRAF3IP3 in malignant melanoma can inhibit tumor growth. The role of TRAF3IP3 in glioma is unknown. METHODS: We used the Wilcoxon rank sum test to compare the expression of TRAF3IP3 in glioma and normal tissues based on The Cancer Genome Atlas and Genotype Tissue Expression. Logistics regression was used to evaluate the relationship between TRAF3IP3 and clinicopathologic characters. Gene set enrichment analysis and single-sample gene set enrichment analysis were conducted to annotate biological function of TRAF3IP3. We used Kaplan-Meier and Cox regression to evaluate the prognostic value of TRAF3IP3. RESULTS: We downloaded RNA-seq data of 670 gliomas and 1157 normal tissues. TRAF3IP3 was highly expressed in gliomas (P < 0.001). High expression of TRAF3IP3 and higher World Health Organization grade (odds ratio [OR], 3.57 [2.42-5.34 CI]; P < 0.001), wild-type isocitrate dehydrogenase status (OR, 4.79 [3.40-6.83 CI]; P < 0.001), 1p/19q non-codeletion (OR, 15.32 [9.23-27.01 CI]; P < 0.001), mutant epidermal growth factor receptor status (OR, 2.77 [1.65-4.81 CI]; P < 0.001), worse histologic type (OR, 3.64 [2.48-5.43 CI]; P < 0.001) and worse primary therapy outcome (OR, 2.29 [1.47-3.61 CI]; P < 0.001) were significantly correlated. Six signaling pathways were significantly enriched in the TRAF3IP3 high-expression phenotype group, including JAK-STAT, interferon-γ, apoptosis, P53, programmed cell death protein 1, and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4). High expression of TRAF3IP3 was associated with worse progression-free survival (hazard ratio [HR], 2.39 (1.39-3.01); P < 0.001), disease-free survival (HR, 3.02 (2.27-4.01); P < 0.001) and overall survival (HR, 2.87 (2.20-3.75); P < 0.001). CONCLUSIONS: TRAF3IP3 play an important role in the occurrence and development of glioma and may be a potential biomarker for the prognosis of glioma.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Yang G, Tang S, Zhang J, et al. High TRAF3IP3 Level Predicts Poor Prognosis of Patients with Gliomas. World Neurosurg. 2021. PMID: 33444836. doi:10.1016/j.wneu.2021.01.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。